Genetic Screening for Right Ventricular Failure: Potential for Earlier Transplant Referral

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Circulation https://doi.org/10.1161/CIRCULATIONAHA.125.078674 
Dr. Yongneng Zhang  et al.

Points

Researchers identified a specific genetic variant present in approximately thirty percent of pulmonary arterial hypertension patients that serves as a reliable predictor for early and rapid right heart failure.
The study utilized heart tissue samples from three major academic institutions to confirm that carriers of this variation face a significantly higher risk of fast cardiac decompensation than non-carriers.
Systemic inflammation was also discovered to be a major driver of early heart failure, particularly in patients suffering from comorbid autoimmune diseases like lupus or the skin condition scleroderma.
Scientists aim to implement a simple mouth swab test for this genetic variant to help clinicians identify which high-risk individuals require more frequent follow-up care and more intense treatments.
Earlier identification of these patients could improve survival rates by allowing for more timely referrals to heart transplant programs before their cardiac function deteriorates beyond the point of effective intervention.

Summary

This study evaluated the genetic and inflammatory drivers of right ventricular (RV) decompensation in patients with pulmonary arterial hypertension (PAH). While RV failure is the primary cause of morbidity and mortality in PAH—with approximately 50% of patients dying within five years of diagnosis—the rate of transition from compensated to decompensated states varies significantly. The research sought to identify biomarkers that could predict rapid RV failure to prioritize high-risk patients for intensive intervention and heart transplantation.

Using rat models and heart tissue analysis from patient cohorts at the University of Alberta, Laval University, and Duke University, the team identified a specific genetic variant in approximately 30% of the population that predisposes individuals to accelerated RV failure. Carriers of this single nucleotide polymorphism (SNP) in the UCP2 gene exhibited faster cardiac decompensation compared to non-carriers. Additionally, the study found that systemic inflammation acts as a significant contributor to early failure, particularly in patients with comorbid inflammatory conditions such as scleroderma or lupus.

The findings suggest that the detection of this genetic variant via mouth swab, combined with inflammatory markers from blood tests, could provide a scalable method for clinical risk stratification. Identifying the 30% of the PAH population at highest risk for rapid deterioration would allow for more frequent follow-up, escalation of medical therapy, and earlier referral for surgical consultation. Future research will focus on validating these results in larger prospective populations to establish a standardized protocol for integrating genetic screening into the management of pulmonary vascular disease.

Link to the article: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.078674

References

Zhang, Y., Bonnet, S., Provencher, S., Piao, J., Haromy, A., Liu, Y., Zhao, Y.-Y., Breuils-Bonnet, S., Lemay, S.-E., Bowles, D. E., Mendiola Pla, M., Sutendra, G., & Michelakis, E. D. (2026). A critical contribution of cardiac myofibroblasts in right ventricular failure and the role of ucp2 snps in the predisposition to rv decompensation in pulmonary arterial hypertension. Circulation, CIRCULATIONAHA.125.078674. https://doi.org/10.1161/CIRCULATIONAHA.125.078674